ev3 — Q4 2008 Earnings Presentation
20 slides from ev3's earnings presentation, Feb 24, 2009
Slide 1: Q4 '08 Highlights
Q4 '08 Highlights February 24, 2009
Slide 2: Forward-Looking Statements
Forward-Looking Statements Statements contained in this presentation that relate to future, not past, events are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Forward-looking statements often can be identified by words such as "expect," "anticipate," "estimat
Slide 3: Use of Non-GAAP Financial Measures
Use of Non-GAAP Financial Measures ev3 uses certain non-GAAP financial measures in this presentation, including "non- GAAP adjusted net income (loss)," "non-GAAP adjusted net earnings (loss) per share," "net sales, excluding atherectomy and research collaboration revenues," and "peripheral vascular
Slide 4: Q4 '08 Financial Summary
Q4 '08 Financial Summary Net sales of $106.1 million were up +15% vs. Q4 2007 Product sales of $105.6M were in line with previous guidance of $102-$107M Non-GAAP adjusted net EPS* of $0.08 exceeded the high end of our guidance range by 2 cents Non-GAAP adjusted net income (loss)* improved to income
Slide 5: Actual Results vs. Last Quarter & Year Ago
Actual Results vs. Last Quarter & Year Ago *Fourth quarter 2007 excludes FoxHollow atherectomy sales of approximately $3.9 million for the first four days of the quarter prior to the completion of the merger. **All quarters presented are adjusted for amortization and non-cash stock-based compensatio
Slide 6: Total Q4 '08 Revenue Growth of 15%
Total Q4 '08 Revenue Growth of 15% Q1 Q2 Q3 Q4 Q4 East 101.3 107.7 107 92.2 106.1 Total Worldwide ev3 ($M) +15% Q1 Q2 Q3 Q4 Q4 East 34.8 35.9 36.6 28 39.4 Total International ($M) +41% Q1 Q2 Q3 Q4 Q4 East 64.1 70.8 66.9 57.9 68.1 Worldwide Peripheral Vascular ($M) +18% Q1 Q2 Q3 Q4 Q4 East 31 30.7 33
Slide 7: Balance Sheet is Strengthening
Q1 Q2 Q3 Q4 East 57 38.7 45.9 59.7 2008 Balance Sheet is Strengthening Cash / Cash Equivalents Cash/cash equivalents increased $13.7M Q4 '08 vs Q3 '08 Inventory days down 11% in Q4 '08 vs Q3 '08 Total debt is minimal at $9.0M 7
Slide 8: Financial Summary: Continuing to Improve Performance
Financial Summary: Continuing to Improve Performance Net Product Sales* $86,271 $95,050 $101,509 $100,018 $105,656 Gross Profit $57,200 $67,639 $71,528 $68,747 $71,316 Gross Margin 62.0% 66.8% 66.4% 64.2% 67.2% Net Loss $(107,867) $(9,770) $(27,422) $(7,310) $(291,120) Adjusted net EPS (loss) per di
Slide 9: Guidance - As of February 24, 2009
Guidance - As of February 24, 2009 Expect Full-Year 2009 Positive GAAP EPS Revenues: Q1 2009: $95 to $99 million Full-Year 2009: $415 to $430 million Adjusted EPS (loss)1 per diluted share: Q1 2009: $(0.03) to $0.001,2 Full-Year 2009: $0.38 to $0.441,2 Adjusted EPS (loss) guidance is based on weight
Slide 10: Business Model Structure - Select P&L Information
2008 % of sales 2007 2009 Goal Business Model Structure - Select P&L Information Sales 100% 100% 100% Gross margin 66% 65% 70% Selling, general & administrative 55% 69% 49% Taxes 0.4% 0.3% 1% Research & development 12% 17% 12% Stock-based comp & amortization 11% 11% 9% Adjusted net income (loss)* 2.
Slide 11: Pathway to Profitable Growth
Pathway to Profitable Growth Long-term profitable revenue growth Improve cost structure Increase sales force productivity Grow international sales Clinical evidence New products 1 2 3 4 5
Slide 12: 1. Improve Cost Structure - Continuing Progress
1. Improve Cost Structure - Continuing Progress Q4 07 Q4 08 East 0.76 0.5 SG&A % of sales R&D % of sales Q4 07 Q4 08 East 0.21 0.1 Additional reductions in COGS and SG&A planned in 2009 Continued focus on improving margins 12
Slide 13: 2. Increase Peripheral Vascular Sales Force Productivity in U.S.
Annualized Net Sales Per Territory Q4'08 up 15% vs. Q4'07 Key Drivers Atherectomy Clinical Specialists Corporate Account penetration Referral Market development DEFINITIVE clinical data Neuro business already > $2M per territory 13 Q4'07 Q2'08 Q4'08 Goal East 1.3 1.5 1.5 2 2. Increase Peripheral Vas
Slide 14: 3. Continue Strong Momentum in International
2003 2004 2005 2006 2007 2008 East 30 44 62 81 107 147 3. Continue Strong Momentum in International *Translated to U.S. Dollars at the applicable or estimated foreign exchange rate for the periods presented 14 International Revenue* ($M) 37% CAGR
Slide 15: 4. Broad Clinical Trial Initiatives to Support Procedure Adoption
4. Broad Clinical Trial Initiatives to Support Procedure Adoption Designed to expand clinical evidence, support regulatory clearances and expand product indications Clinical Name Clinical Trial Description Study Timeline SWIFT Ischemic stroke flow restoration; Safety: Device-related and procedure-re
Slide 16: 5. New Products Driving Growth
'07A '08A '09E East 278 402 430 $278M $402M ~$415-$430M 5. New Products Driving Growth Key Drivers Product Revenue Growth* Global PTA Balloon Launch EverCross(tm) .035 NanoCross(tm) .014 ..018 PTA Balloon in 2H '09 Expanded Atherectomy Toolkit RockHawk(tm) and TurboHawk(tm) PowerCross Guidewire Supp
Slide 17: Upcoming Product Launch: New AXIUM Microfilament Coil Systems
Upcoming Product Launch: New AXIUM(tm) Microfilament Coil Systems Enhanced microfilament technology creates lattice effect enabling increased acute occlusion and packing volume Designed to accelerate acute and long-term healing Two microfilament versions: Axium PGLA co-polymer and Axium Nylon Antici
Slide 18: Next Generation PTA Balloons: EverCross .035 and NanoCross .014
Next Generation PTA Balloons: EverCross .035 and NanoCross .014 Innovative beveled tip profiles for best-in-class lesion entry Broad range of sizes, including only 200mm length .035 balloon available worldwide Access to key markets with significantly improved margins Full global launch in progress E
Slide 19: Why Invest in ev3
Why Invest in ev3 I N S U M M A R Y 19 Broadest product offering in $2B growing global market largest pure-play in endovascular market Clear roadmap for sustained, profitable growth improved costs, productivity, clinical evidence, new products Company refocused in 2008 to achieve future profitabilit
Slide 20: Q4 '08 Highlights
Q4 '08 Highlights February 24, 2009